Telmisartan Attenuates the Growth of Epithelium-like Cells and Glomerular Injury in Spontaneously Hypertensive Rats

Abstract

The abnormal growth of epithelium-like cells has been noticed in spontaneously hypertensive rats (SHRs) with hypertensive nephropathy. However, the characteristics of abnormal epithelium-like cells and their pathogenesis in hypertensive nephropathy are not fully understood. In the present study, we investigated the correlation of epithelium-like cells with glomerular injury, and the effects of early drug intervention with telmisartan, an anti-hypertensive drug, on the growth of epithelium-like cells. The results showed that the epithelium-like cells were obviously observed lining along the luminal surface of Bowman’s capsule in glomeruli, significantly resulting in the atrophy of the glomerular tuft. Some of the epithelium-like cells strongly expressed proliferating cell nuclear antigen (PCNA) and vimentin, indicating active cellular proliferation. The incidence of epithelium-like cells varied from 13.6% to 54.4% of glomeruli in 48-week-old SHRs, and from 5.1% to 18.0% of glomeruli in age-matched Wistar-Kyoto (WKY) rats (P<0.01). The linear regression analysis further confirmed an obvious correlation between the incidence of epithelium-like cells and the glomerular injury. Moreover, early intervention with telmisartan could dramatically attenuate the progression of epithelium-like cells growth. However, no significant effect of telmisartan on the established epithelium-like cells was observed. Taken together, we demonstrated the involvement of abnormal epithelium-like cells growth in glomerular injury during hypertensive nephropathy in SHRs, and firstly showed the positive effects of the anti-hypertensive drug on the progression of epithelium-like cells growth.

Keywords

hypertension / epithelium-like cell / glomerular injury / telmisartan / spontaneously hypertensive rats (SHRs)

References

[1] ManciaG, SchumacherH, RedonJ, et al.. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, 124(16): 1727-1736

[2] MunkhaugenJ, LydersenS, WideroeTE, et al.. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis, 2009, 54(4): 638-646

[3] HultstromM. Development of structural kidney damage in spontaneously hypertensive rats. J Hypertens, 2012, 30(6): 1087-1091

[4] BidaniAK, GriffinKA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension, 2004, 44(5): 595-601

[5] MennuniS, RubattuS, PierelliG, et al.. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens, 2014, 28(2): 74-79

[6] TurnerRJ, BloemenkampKW, PenningME, et al.. From Glomerular Endothelium to Podocyte Pathobiology in Preeclampsia: a Paradigm Shift. Curr Hypertens Rep, 2015, 17(7): 54

[7] CondeK, RoyS, FreakeHC, et al.. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig. Lipids, 1999, 34(12): 1327-1332

[8] LuqueY, LenoirO, BonninP, et al.. Endothelial Epas1 Deficiency Is Sufficient To Promote Parietal Epithelial Cell Activation and FSGS in Experimental Hypertension. J Am Soc Nephrol, 2017, 28(12): 3563-3578

[9] ValdesAJ, ZhangJM. Intraglomerular tubular epithelial cells. A marker of glomerular hematuria. Arch Pathol Lab Med, 1987, 111(2): 189-191

[10] WaughD, SchlieterW, JamesAW. Infraglomerular Epithelial Reflux. An Early Lesion of Acute Renal Failure. Arch Pathol, 1964, 77: 93-96

[11] Garcia-CaceresU. Histologic aspects of subacute glomerulonephritis; with special reference to proliferative alterations in the epithelium of renal tubules. Am J Pathol, 1959, 35(4): 755-767

[12] KanelGC, PetersRL. Glomerular tubular reflux—a morphologic renal lesion associated with the hepatorenal syndrome. Hepatology, 1984, 4(2): 242-246

[13] IsaacJ, TogelFE, WestenfelderC. Extent of glomerular tubularization is an indicator of the severity of experimental acute kidney injury in mice. Nephron Exp Nephrol, 2007, 105(1): e33-e40

[14] SimonF, ScheuerleA, GrogerM, et al.. Effects of intravenous sulfide during porcine aortic occlusion-induced kidney ischemia/reperfusion injury. Shock, 2011, 35(2): 156-163

[15] Moya-OlanoL, MilneHM, RobinsonJM, et al.. Trientine and renin-angiotensin system blockade ameliorate progression of glomerular morphology in hypertensive experimental diabetic nephropathy. Pathol Int, 2011, 61(11): 652-661

[16] KusunokiH, TaniyamaY, AzumaJ, et al.. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-gamma/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade. Hypertension, 2012, 59(2): 308-316

[17] BensonSC, PershadsinghHA, HoCI, et al.. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004, 43(5): 993-1002

[18] ZhangZ, LiZ, CaoK, et al.. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy. J Hypertens, 2017, 35(7): 1442-1456

[19] BakrisG, BurgessE, WeirM, et al.. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int, 2008, 74(3): 364-369